Moderna’s two-dose COVID-19 vaccine was 44% effective at preventing infection from Omicron in children 6 months to under 2 years old and roughly 38% effective for children ages 2 to 5 years, according to data released by the company on Wednesday (March 23).
Breaking News: Moderna will seek emergency authorization of its coronavirus vaccine for children younger than 6, the company said.https://t.co/6TnE4gNPhH
— The New York Times (@nytimes) March 23, 2022
None of the children in the trial developed severe illness from COVID-19 and the majority of breakthrough cases were mild, according to the biotech company.
BREAKING: The nation's 18 million children under 5 are the only age group not yet eligible for vaccination. Moderna says its low-dose shots could change that. https://t.co/O9NMjziVSC
— CBS News (@CBSNews) March 23, 2022
Moderna will ask the FDA to grant emergency use authorization for the vaccine for children under 6 years old as soon as possible, CEO Stephane Bancel said in a statement.